drugset / Trial / NCT03869762
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
NaSingle-groupOpen-labelTreatment
Summary
Open-label phase II multi-centre single arm study of Denosumab in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Timeline
- Start
- 2019-01-09
- Primary completion
- 2019-01-12
- Completion
- 2019-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |